The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma

Bladder cancer (BC) or carcinoma (BLCA) is predominantly derived from urothelium and includes non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). Bacillus Calmette-Guerin (BCG) has long been applied for NMIBC to effectively reduce disease recurrence or progression, whereas immune checkpoin...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Huiyang Yuan, Yuchen Xiu, Tiantian Liu, Yidong Fan, Dawei Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Subjects:	BCG cuproptosis ICI immunotherapy prognosis bladder carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1126247/full

Similar Items

Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
by: Cindy Garcia, et al.
Published: (2016-01-01)

Intravescical instillation of Calmette-Guérin bacillus and COVID-19 risk
by: Ugo Fedeli, et al.
Published: (2021-02-01)

Successful treatment with low‐dose oral steroids for contracted bladder after intravesical instillation of Bacillus Calmette–Guérin
by: Akinobu Katami, et al.
Published: (2024-03-01)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
by: Fumie Yoshioka, et al.
Published: (2023-03-01)

Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
by: Chung Un Lee, et al.
Published: (2023-11-01)

Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches
by: Maoxin Lv, et al.
Published: (2024-08-01)

Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer
by: Omar M. Ibrahim, et al.
Published: (2024-04-01)

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion
by: Tao‐nong Cai, et al.
Published: (2023-12-01)

A case of mycotic infrarenal abdominal aortic aneurysm after bacillus Calmette-Guérin immunotherapy for bladder cancer and a review of the literature
by: Vinojan Satchithanantham, MD, FEBVS, FRCSEd, et al.
Published: (2023-09-01)

The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
by: Jong Ho Park, et al.
Published: (2024-11-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer
by: Shahram Ahmadi, et al.
Published: (2024-04-01)

Bacillus Calmette–Guérin Immunotherapy for Cancer
by: Fabíola Cardillo, et al.
Published: (2021-05-01)

Afebrile tuberculous prostatic abscess with rectal fistula after intravesical Bacillus Calmette‐Guérin immunotherapy
by: Tatsuhiro Sawada, et al.
Published: (2025-01-01)

Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
by: Zongren Wang, et al.
Published: (2018-11-01)

Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
by: Dong Ha Kim, et al.
Published: (2024-12-01)

Efficacy Study of Mitomycin C Pre-infusion in Addition to Periodic Bacillus Calmette-Guerin Infusions in the Management of Non-muscle Invasive Bladder Cancers
by: Deepika Agrawal, et al.
Published: (2021-12-01)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia
by: Chamodi Pillippu Hewa, et al.
Published: (2024-02-01)

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
by: Jiwoong Yu, et al.
Published: (2023-11-01)

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer
by: Charles J. Rosser, et al.
Published: (2021-01-01)

The role of Uro-Vaxom in reducing infectious adverse effects and improving outcomes in bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer
by: Sookyung Cho, et al.
Published: (2025-07-01)

Systemic immune-inflammation index holds high prognostic value in patients undergoing Bacillus Calmette-Guerin -immunotherapy for bladder cancer
by: Zhaoxiang Wang, et al.
Published: (2022-02-01)

Protective role of Bacillus Calmette–Guérin vaccine in Alzheimer's disease progression: A systematic review and meta-analysis
by: Tungki Pratama Umar, et al.
Published: (2024-03-01)

Predictive value of tumor invasion patterns on intravesical bacillus Calmette–Guérin response for stage T1 high-grade non-muscle-invasive bladder cancer
by: Ismail Ulus, et al.
Published: (2025-07-01)

Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)
by: Jake Tempo, et al.
Published: (2023-11-01)

A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01)

Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette–Guérin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer
by: Junghoon Lee, et al.
Published: (2023-10-01)

Miliary tuberculosis following intravesical Bacillus Calmette and Guérin therapy: A rare complication of a frequent procedure
by: Lobna Loued, et al.
Published: (2021-09-01)

Breast abscess due to Bacillus Calmette-Guérin
by: Aurélien Dinh, et al.
Published: (2017-06-01)

Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01)

Newly sequenced genomes of four Bacillus Calmette Guerin vaccines
by: Maria Carolina Sisco, et al.
Published: (2020-05-01)

Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
by: Kylie Yen‐Yi Lim, et al.
Published: (2025-04-01)

Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China
by: Junli Li, et al.
Published: (2022-07-01)

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer
by: Wenlong Zhong, et al.
Published: (2020-01-01)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
by: Girish S. Kulkarni, et al.
Published: (2022-07-01)

A severe Bacillus Calmette-Guérin vertebral osteomyelitis requiring spinal stabilization: a clinical and microbiological investigation
by: Giuliana Carrega, et al.
Published: (2023-06-01)

Peripheral Mechanisms Underlying Bacillus Calmette–Guerin-Induced Lower Urinary Tract Symptoms (LUTS)
by: Meera Elmasri, et al.
Published: (2024-11-01)

An ambivalent prostate nodule after Bacillus Calmette-Guérin therapy
by: Léo Sauvat, et al.
Published: (2021-01-01)

Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?
by: Renata Monteiro-Maia, et al.
Published: (2014-09-01)